{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:19:04Z","timestamp":1679231944636},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamaoncol.2018.0111","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T16:31:16Z","timestamp":1522341076000},"page":"859","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Talal","family":"Hilal","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"9759","key":"ces180001r1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"21","key":"ces180001r2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy.","volume":"122","author":"Salles","year":"2013","journal-title":"Blood"},{"issue":"3","key":"ces180001r4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1179\/1607845414Y.0000000179","article-title":"Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.","volume":"20","author":"Zhou","year":"2015","journal-title":"Hematology"},{"issue":"27","key":"ces180001r5","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","article-title":"Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.","volume":"31","author":"Vitolo","year":"2013","journal-title":"J Clin Oncol"},{"key":"ces180001r6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma: individual patient data meta-analysis.","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"issue":"14","key":"ces180001r7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma.","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"ces180001r3","author":"Salles","year":"2017"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2676219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T17:54:03Z","timestamp":1570989243000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.0111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.0111","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}